To investigate whether purine biosynthesis regulates myeloid differentiation of LSCs, we isolated LSCs from the MLL-AF9-induced AML mouse model and treated them with purine biosynthesis inhibitors mycophenolate mofetil (MMF), mycophenolic acid (MPA), or 6-mercaptopurine (6-MP). This evidence concerns the gene KMT2A and acute myeloid leukemia.